MX2023012826A - Tratamiento de enfermedades oculares utilizando antagonistas del receptor de endotelina. - Google Patents
Tratamiento de enfermedades oculares utilizando antagonistas del receptor de endotelina.Info
- Publication number
- MX2023012826A MX2023012826A MX2023012826A MX2023012826A MX2023012826A MX 2023012826 A MX2023012826 A MX 2023012826A MX 2023012826 A MX2023012826 A MX 2023012826A MX 2023012826 A MX2023012826 A MX 2023012826A MX 2023012826 A MX2023012826 A MX 2023012826A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- receptor antagonists
- eye diseases
- endothelin receptor
- eye
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182750P | 2021-04-30 | 2021-04-30 | |
| PCT/US2022/027045 WO2022232586A1 (en) | 2021-04-30 | 2022-04-29 | Treatment of ocular diseases using endothelin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012826A true MX2023012826A (es) | 2023-11-13 |
Family
ID=83848733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012826A MX2023012826A (es) | 2021-04-30 | 2022-04-29 | Tratamiento de enfermedades oculares utilizando antagonistas del receptor de endotelina. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240058265A1 (https=) |
| EP (1) | EP4329810A4 (https=) |
| JP (1) | JP2024516829A (https=) |
| CN (1) | CN117295520A (https=) |
| AU (1) | AU2022264438A1 (https=) |
| CA (1) | CA3218398A1 (https=) |
| IL (1) | IL307794A (https=) |
| MX (1) | MX2023012826A (https=) |
| WO (1) | WO2022232586A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4329753A4 (en) * | 2021-04-30 | 2025-02-26 | Perfuse Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002049630A2 (en) * | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Method for preventing or treating pain by administering an endothelin antagonist |
| US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| BRPI1013904A2 (pt) * | 2009-04-30 | 2016-07-19 | Univ Midwestern | método e composição para tratar cetoacidose diabética |
| US20120087864A1 (en) * | 2010-04-12 | 2012-04-12 | R-Tech Ueno, Ltd. | Method for diagnosing and/or evaluating retinal disease |
| CA2949954A1 (en) * | 2014-05-23 | 2015-11-26 | Ocular Technologies Sarl | Topical formulations and uses thereof |
| WO2018185516A1 (en) * | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| JP2020528082A (ja) * | 2017-07-17 | 2020-09-17 | ロイズマン，キース | 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達 |
| EP4050997A4 (en) * | 2019-10-30 | 2022-11-30 | Perfuse Therapeutics, Inc. | TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS |
| CA3168810A1 (en) * | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
| EP4329753A4 (en) * | 2021-04-30 | 2025-02-26 | Perfuse Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES |
-
2022
- 2022-04-29 CA CA3218398A patent/CA3218398A1/en active Pending
- 2022-04-29 CN CN202280032071.2A patent/CN117295520A/zh active Pending
- 2022-04-29 WO PCT/US2022/027045 patent/WO2022232586A1/en not_active Ceased
- 2022-04-29 EP EP22796855.9A patent/EP4329810A4/en active Pending
- 2022-04-29 MX MX2023012826A patent/MX2023012826A/es unknown
- 2022-04-29 JP JP2023566519A patent/JP2024516829A/ja active Pending
- 2022-04-29 IL IL307794A patent/IL307794A/en unknown
- 2022-04-29 AU AU2022264438A patent/AU2022264438A1/en active Pending
-
2023
- 2023-10-25 US US18/494,545 patent/US20240058265A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240058265A1 (en) | 2024-02-22 |
| WO2022232586A1 (en) | 2022-11-03 |
| EP4329810A4 (en) | 2025-02-26 |
| EP4329810A1 (en) | 2024-03-06 |
| CN117295520A (zh) | 2023-12-26 |
| IL307794A (en) | 2023-12-01 |
| CA3218398A1 (en) | 2022-11-03 |
| JP2024516829A (ja) | 2024-04-17 |
| AU2022264438A1 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG191334A1 (en) | Use of a vegf antagonist to treat angiogenic eye disorders | |
| AR052172A1 (es) | Inhibicion por arni de ctgf pra el tratamiento de trastornos oculares | |
| MX2015001741A (es) | Endoprotesis de collar ocular para tratar estrechamiento del angulo iridocorneo. | |
| MY176514A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| MX2022001433A (es) | Tratamiento personalizado de enfermedades oftalmologicas. | |
| EP4527447A3 (en) | Ocular microcurrent stimulation therapy apparatus | |
| HK1201438A1 (en) | Treatment of ocular disease | |
| MX2020010968A (es) | Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades. | |
| ZA202204939B (en) | Compounds for treatment of eye diseases associated with excessive vascularisation | |
| MX2022005063A (es) | Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina. | |
| TN2019000112A1 (en) | Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma | |
| JOP20230133A1 (ar) | استخدام منشطات sGC لمعالجة الأمراض العينية | |
| MX2023011426A (es) | Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada. | |
| MX2020012011A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| MX391627B (es) | Aplicación cuantitativa periorbital de fármacos oftalmológicos. | |
| MX2023012826A (es) | Tratamiento de enfermedades oculares utilizando antagonistas del receptor de endotelina. | |
| ZA202309651B (en) | Compositions and methods for treatment of ocular disease associated with angiogenesis | |
| MX2019011242A (es) | Farmacos y composiciones para el tratamiento de trastornos oculares. | |
| EA201992356A1 (ru) | Способ и композиция для лечения заболевания, связанного с сетчаткой глаза, с использованием ингибитора ccr3 | |
| EA200700772A1 (ru) | Аналоги полиаминов в качестве терапевтических средств для глазных заболеваний | |
| EP4362923A4 (en) | Pharmacological agents for preventing and treating cataracts and presbyopia eye diseases | |
| MX2020011535A (es) | Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. | |
| MX384567B (es) | Preparacion oftalmologica | |
| JOP20250312A1 (ar) | جرعة عالية ممتدة من نظم علاجية لمضاد vegf لعلاج اضطرابات العين وعائية المنشأ | |
| HK1189820A (en) | Use of a vegf antagonist to treat angiogenic eye disorders |